Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anadys Pharmaceuticals Inc.
Isatoribine lowers plasma hepatitis C RNA in chronically infected patients
October 26th, 2005
Isatoribine lowers plasma hepatitis C RNA in chronically infected patients. "Immune-based therapy is the mainstay treatment for chronic hepatitis C virus (HCV) infection but causes multiple side effects and achieves durable viral clearance in only approximately 50% of patients. Most new investigational anti-HCV compounds are direct-acting antivirals for which durability of response and risk of viral mutations and resistance are not yet known," scientists writing in the journal Hepatology report. "Therefore, continuing discovery and development of new immune-based treatments is desirable. Toll-like receptors (TLRs) are pathogen recognition...
Source: Elder Law Weekly (2005-10-26)
|
